Domainex offers services including highly experienced computational and medicinal chemistry and a unique patented technology called CDH. . . Our unique LeadBuilder technology for finding in a highly cost effective manner robust developable hits. LeadBuilder has been used many times for clients in the academic or biotech areas with great effect. Our medicinal chemistry expertise is based upon a team of highly experienced medicinal chemists based in Cambridge with a history of working for leading European Pharma and Biotech. We specialise in tackling a broad range difficult targets for drug discovery, including peptidomimetics.. . Combinatorial Domain Hunting or CDH is a unique patented technology conceived by Prof Laurence Pearl’s team of leading structural biologists and is specifically aimed at expressing protein targets for drug discovery that can not be expressed by other approaches. CDH has been applied to targets from many leading Pharma.. . Domainex also has its own drug discovery pipeline. Domainex’s lead project is IKK epsilon which is in lead optimisation for breast cancer. Domainex also has a pipeline of lysine methyl transferases (KMTs) all targeted at cancer. Our unique CDH technology has been applied to a number of KMTs with the aim of producing unique x-ray structures and assays.
I am a freelance consultant and a science and medical writer. I trained in physics before switching to biophysics for my PhD (later bioinformatics) and spent nine years as a postdoctorate in the UK and US before changing careers in 1998. I still teach to MSc level; bioinformatics and structural biology at Birkbeck, University of London and medicinal chemistry at the Opeu University. I write news and features in print and online for a specialist scientific and medical readership; provide specialist editing services; and offer support, training and capacity building in bioinformatics and related subjects within academia and industry.
Custom Pharma Services (CPS) as a strategic business unit of Dr Reddy’s draws on years of knowledge and expertise in pharmaceutical development and manufacturing to provide innovators with customised services and solutions for intermediates, active ingredients and finished dosages. Within a short span, we have become one of the largest pharmaceutical outsourcing players from India and a global partner-of-choice. We have a track record of bringing innovations to the market quickly, efficiently and economically with the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. Our end-to-end services make a compelling value proposition to our global innovator customers.
The Earlham Institute (EI) is a research institute applying advanced genomics and computational approaches to aid our understanding of complex biological systems and their interaction with the environment.
Established in 2009 and located on the Norwich Research Park, EI is strategically funded by the UK’s Biotechnology and Biological Sciences Research Council (BBSRC).
The Earlham Institute (EI) uses expertise in genomics, bioinformatics and molecular biology to answer complex biological questions and improve plant and animal health, and tackle global issues of food security, climate change, conservation and human wellbeing.
EI is home to state-of-the-art laboratories, specialist equipment and facilities enabling genomics and bioinformatics research, including one of the largest supercomputing facilities for life science research in Europe.
Our technology platforms include:
• Genomics and Single-Cell Analysis facility that provides scalable infrastructure for high-throughput DNA/RNA analysis of biological systems.
• BIO Foundry facility that provides services for high-throughput, nanoscale DNA-assembly, low-cost sequence validation of synthetic constructs and microfermentation.
• High-Performance Computing platform that provides access to high-throughput computing clusters and data management support.
• State-of-the-art training facility for bioinformatics and genomics with expert-led courses.
EI has established collaborative projects worldwide. We are involved in collaborative R&D projects with industry through consultancy, contract research, and grant funding.
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.. EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:. •
EIP is an innovative Intellectual Property law firm advising on all areas of IP. EIP has more than 60 professional staff practising from its four UK offices in Bath, Cardiff, Leeds and London, its US office in Denver and its German office in Dusseldorf. EIP Life is our life sciences and medical devices team which has a wealth of technical knowledge and experience in dealing with the biotechnology and health sectors, for start-ups and major multinationals.
Lilly is developing a growing portfolio of best in class pharmaceutical products by applying the latest research from our own laboratories and from collaborations with eminent scientific organisations worldwide. In 2003 the company's world-wide sales were more than $12 billion. Lilly employs more than 43000 people worlwide and markets medicines in 158 countries. Lilly Research Laboratories (the R&D division of the company) employs more than 8000 people from a wide variety of disciplines. The company has R&D facilities in 9 countries and currently conducts clinical trials in more then 60 countries around the world. . . Lilly's internal research efforts are focused in the following major therapeutic areas: cancer, cardiovascular diseases, endocrinology, neuroscience, gene regulation, bone biology, immunomodulation and Inflammation Compounds in late stage development, and those currently being launched have promise to address the needs of patients with sepsis, cancer, diabetes, depression, osteoporosis, erectile dysfunction, urinary incontinence and attention deficit hyperactivity disorder.. . In pursuit of innovation Lilly seeks to incorporate those cutting edge technologies which support the high quality, rapid identification and investigation of novel compounds.. . The company approach to innovation includes a commitment to the philosophy of research without walls - a stated commitment to partnership and external collaboration. Currently Lilly Research Laboratories has more than 120 active collaborations with external scientists.